Literature DB >> 14582034

Stem-cell therapy for renal diseases.

Daniel J Mollura1, Joshua M Hare, Hamid Rabb.   

Abstract

Significant attention is currently directed to the biological and therapeutic capabilities of stem cells for developing novel treatments for acute and chronic kidney diseases. To date, viable sources of stem cells for renal therapies include adult bone marrow and embryonic tissues, including the metanephric mesenchyme and mesonephros. Native adult kidney stem cells have yet to be identified. Systemically introduced stem cells can engraft in sites of renal disease and injury to show donor phenotypes. Stem cells can differentiate into cells similar to glomeruli, mesangium, and tubules in the kidneys. The impact of stem-cell engraftment and differentiation on renal function presently is unknown. Identification of renal diseases treatable with stem-cell therapies is expected to evolve as stem-cell technologies advance. Methods of modifying stem cells to improve homing, differentiation, and integration into host tissues need further characterization. Ethical and legal controversies about embryonic research and cloning are shaping the regulation and funding of stem-cell research for kidney diseases. Scientific and clinical understanding of stem cells and their potential for renal treatments are in the early stage of development. This field offers great promise, and there are significant opportunities for future investigation in clinical, biological, and ethical aspects of stem-cell therapy for kidney diseases.

Entities:  

Keywords:  Biomedical and Behavioral Research; Genetics and Reproduction; Health Care and Public Health

Mesh:

Year:  2003        PMID: 14582034     DOI: 10.1016/j.ajkd.2003.07.018

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  4 in total

Review 1.  Postnatal development, maturation and aging in the mouse cochlea and their effects on hair cell regeneration.

Authors:  Bradley J Walters; Jian Zuo
Journal:  Hear Res       Date:  2012-11-16       Impact factor: 3.208

2.  Immunohistochemical localisation of TRA-1-60, TRA-1-81, GCTM-2 and podocalyxin in the developing baboon kidney.

Authors:  Lina Gubhaju; Andrew Laslett; John F Bertram; Anthony Zulli; M Jane Black
Journal:  Histochem Cell Biol       Date:  2008-02-12       Impact factor: 4.304

Review 3.  Clinical and genetic approach to renal hypomagnesemia.

Authors:  Min-Hua Tseng; Martin Konrad; Jhao-Jhuang Ding; Shih-Hua Lin
Journal:  Biomed J       Date:  2021-11-10       Impact factor: 7.892

Review 4.  Synthetic Biology Technologies And Genetically Engineering Strategies For Enhanced Cell Therapeutics.

Authors:  Siyu Li; Hao Tang; Cheng Li; Jiajia Ma; Maqsood Ali; Qi Dong; Jiajia Wu; Yang Hui; Chongran Sun
Journal:  Stem Cell Rev Rep       Date:  2022-09-27       Impact factor: 6.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.